These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28657188)

  • 1. From concept(ion) to life after death/the grave: The 'natural' history and life cycle(s) of novel psychoactive substances (NPS).
    Corkery JM; Orsolini L; Papanti D; Schifano F
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28657188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New psychoactive substances: Purchasing and supply patterns in Australia.
    Sutherland R; Bruno R; Peacock A; Dietze P; Breen C; Burns L; Barratt MJ
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28517235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An insight into the deep web; why it matters for addiction psychiatry?
    Orsolini L; Papanti D; Corkery J; Schifano F
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28657187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deconstructing Designer Drugs.
    Sellers EM
    Clin Pharmacol Ther; 2017 Feb; 101(2):167-169. PubMed ID: 27564430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Psychoactive Substances (NPS) - the Hydra monster of recreational drugs.
    Helander A; Bäckberg M
    Clin Toxicol (Phila); 2017 Jan; 55(1):1-3. PubMed ID: 27549399
    [No Abstract]   [Full Text] [Related]  

  • 6. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.
    Pirona A; Bo A; Hedrich D; Ferri M; van Gelder N; Giraudon I; Montanari L; Simon R; Mounteney J
    Int J Drug Policy; 2017 Feb; 40():84-92. PubMed ID: 27956184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations.
    Heyerdahl F; Hovda KE; Giraudon I; Yates C; Dines AM; Sedefov R; Wood DM; Dargan PI
    Clin Toxicol (Phila); 2014 Dec; 52(10):1005-12. PubMed ID: 25361166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4,4'-Dimethylaminorex ("4,4'-DMAR"; "Serotoni") misuse: A Web-based study.
    Loi B; Zloh M; De Luca MA; Pintori N; Corkery J; Schifano F
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28657180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
    Mounteney J; Griffiths P; Sedefov R; Noor A; Vicente J; Simon R
    Addiction; 2016 Jan; 111(1):34-48. PubMed ID: 26419329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile, effects, and toxicity of novel psychoactive substances: A systematic review of quantitative studies.
    Assi S; Gulyamova N; Ibrahim K; Kneller P; Osselton D
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28631432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
    Van Hout MC; Hearne E
    Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring the Internet for emerging psychoactive substances available to Australia.
    Bruno R; Poesiat R; Matthews AJ
    Drug Alcohol Rev; 2013 Sep; 32(5):541-4. PubMed ID: 23647494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of novel psychoactive substances (NPS) use in non-clinical populations: a systematic review protocol.
    Khaled SM; Hughes E; Bressington D; Zolezzi M; Radwan A; Badnapurkar A; Gray R
    Syst Rev; 2016 Nov; 5(1):195. PubMed ID: 27871332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intended and unintended use of cathinone mixtures.
    Guirguis A; Corkery JM; Stair JL; Kirton SB; Zloh M; Schifano F
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28657191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent changes in the clinical features of patients with new psychoactive-substances-related disorders in Japan: Comparison of the Nationwide Mental Hospital Surveys on Drug-related Psychiatric Disorders undertaken in 2012 and 2014.
    Matsumoto T; Tachimori H; Takano A; Tanibuchi Y; Funada D; Wada K
    Psychiatry Clin Neurosci; 2016 Dec; 70(12):560-566. PubMed ID: 27527499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rise of new psychoactive substance use in Australia.
    Burns L; Roxburgh A; Matthews A; Bruno R; Lenton S; Van Buskirk J
    Drug Test Anal; 2014; 6(7-8):846-9. PubMed ID: 24599890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The New Zealand Psychoactive Substances Act (PSA): a policy breakthrough or just a symbolic act?
    Bretteville-Jensen AL
    Addiction; 2014 Oct; 109(10):1590-1. PubMed ID: 25163706
    [No Abstract]   [Full Text] [Related]  

  • 18. New and Emerging Illicit Psychoactive Substances.
    Graddy R; Buresh ME; Rastegar DA
    Med Clin North Am; 2018 Jul; 102(4):697-714. PubMed ID: 29933824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia.
    Anderson C; Morrell C; Marchevsky D
    BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25948854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Someone Else's Problem": New Psychoactive Substances in the Online Hungarian Media.
    Kassai S; Rácz J; Nagy A; Bíbók T; Galambvári É; Kilián C; Gyarmathy VA
    J Psychoactive Drugs; 2017; 49(1):47-51. PubMed ID: 28010181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.